Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06553742
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
High Definition Profiling of Ovarian Cancer Ascites
Sponsor:
None
Organization:
None
Study Overview
Official Title:
High Definition Profiling of Ovarian Cancer Ascites for the Identification of Prognostic Biomarkers and Immunotherapeutic Targets an Integrative Cell of Origin-guided Approach
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This project entails the collection of a prospective cohort of ascites AS samples from High Grade Serous Ovarian Cancer HGSOC patients
High Grade Serous Ovarian Cancer HGSOC is a major cause of cancer-related mortality due to the late-stage diagnosis and failure of surgery and chemotherapy CHT to eradicate the disease with no significant improvement in overall survival
The primary objective of the project is to generate a comprehensive map of ascites cell components detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid
High Grade Serous Ovarian Cancer HGSOC is a major cause of cancer-related mortality due to the late-stage diagnosis and failure of surgery and chemotherapy CHT to eradicate the disease with no significant improvement in overall survival
The primary objective of the project is to generate a comprehensive map of ascites cell components detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid
Detailed Description:
HGSOC is a major cause of cancer-related mortality due to the late-stage diagnosis and failure of surgery and chemotherapy CHT to eradicate the disease with no significant improvement in overall survival
In recent years new therapeutic regimens are being tested to improve the care of HGSOC patients These approaches include the use of poly-ADP-ribose polymerase inhibitors PARPi targeting Homology Directed Repair deficiency anti-angiogenic drugs such as anti-VEGF monoclonal antibodies and immune checkpoint inhibitors that target immune modulation induced by tumor and tumor-associated cells and inflammatory signals Unfortunately the outcome of such therapies has been to date either erratic or dismal
This points to the acute need to identify new biomarkers predictive of treatment response effectively geared to the clinical setting
The primary objective of the project is to generate a comprehensive map of ascites cell components detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid This will allow to define tumoral archetypes reflecting HGSOCs endophenotypes associated with prognosis in patients possibly guiding future refined therapeutical paradigms for ovarian cancer patients and endowing researchers with a well-characterized multilayered dataset for future reference in the context of molecular dissection and target discovery paradigms
Indeed the combination of origin- and archetype-based stratification of HGSOC patients will allow to better identify patients for which existing therapeutical regimens could be beneficial such as the use of checkpoint inhibitors and anti-angiogenic drugs that have been so far erratic in ameliorating patients survival
In recent years new therapeutic regimens are being tested to improve the care of HGSOC patients These approaches include the use of poly-ADP-ribose polymerase inhibitors PARPi targeting Homology Directed Repair deficiency anti-angiogenic drugs such as anti-VEGF monoclonal antibodies and immune checkpoint inhibitors that target immune modulation induced by tumor and tumor-associated cells and inflammatory signals Unfortunately the outcome of such therapies has been to date either erratic or dismal
This points to the acute need to identify new biomarkers predictive of treatment response effectively geared to the clinical setting
The primary objective of the project is to generate a comprehensive map of ascites cell components detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid This will allow to define tumoral archetypes reflecting HGSOCs endophenotypes associated with prognosis in patients possibly guiding future refined therapeutical paradigms for ovarian cancer patients and endowing researchers with a well-characterized multilayered dataset for future reference in the context of molecular dissection and target discovery paradigms
Indeed the combination of origin- and archetype-based stratification of HGSOC patients will allow to better identify patients for which existing therapeutical regimens could be beneficial such as the use of checkpoint inhibitors and anti-angiogenic drugs that have been so far erratic in ameliorating patients survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None